physIQ

18 articles about physIQ

• Oncology Clinician-Scientist Jason Luke, MD Named physIQ Medical Advisor

  10/18/2022

  physIQ announced today that Jason Luke, MD, FACP, a recognized expert in immuno-oncology, professor of medicine, and clinical practitioner has been appointed to the company’s Medical Advisory Board.

• physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health to Accelerate Innovative Phase III Study in Patients with Atrial Fibrillation

  8/24/2022

  physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases.

• PhysIQ Adds NorthShore University HealthSystem to COVID-19 Digital Biomarker Study

  6/15/2021

  NorthShore University HealthSystem has joined physIQ’s NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker.

• Intermountain Healthcare, UTHealth in Houston and Rush University Join PhysIQ’s Study to Develop COVID-19 Digital Biomarker

  5/25/2021

  Digital health leader, physIQ Inc. , recently announced that Intermountain Healthcare Utah , The University of Texas Health Science Center at Houston (UTHealth) and Rush University Medical Center have joined the NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. These institutions will serve as recruiting centers and key partners in the Phase II validation stage of this study.

• PhysIQ, Department of Defense, Duke University, Johns Hopkins and HJF Partner to Study COVID-19

  5/4/2021

  This DOD-funded initiative will assess the role of continuous biosensor data and artificial intelligence in addressing the COVID-19 pandemic.

• PhysIQ Announces Strategic Collaboration to Scale Digital Medicine

  4/20/2021

  physIQ, a leader in real-world biosensor data collection and digital biomarkers, announced a new multi-year collaboration to license physIQ’s accelerateIQTM to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• PhysIQ and U.S. Veteran’s Affairs Advance to Interventional Trial Phase

  2/9/2021

  physIQ, Inc. and the US Department of Veteran’s Affairs have advanced their collaboration to address heart failure care to an interventional trial phase.

• PhysIQ and Purdue University launch study to develop algorithms for detecting earliest signs of COVID-19 from biometric smartwatch data

  9/30/2020

  Certain changes in a person’s heart and breathing rates could precede symptoms of COVID-19, an increasing number of studies suggests. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005184/en/ Purdue University researchers are helping to develop physIQ software that could indicate that a person should get tested for COVID-19 by detecting s

• NorthShore University HealthSystem, Carnegie Mellon University and PhysIQ Launch Comprehensive Study of New Technology to Monitor At-Risk Cardiac and Surgical Patients

  8/5/2020

  NorthShore University HealthSystem, Carnegie Mellon University, and physIQ are collaborating on a multi-phase pilot project using the pinpointIQ™ solution to manage patients with heart failure and patients undergoing ileostomy.

• physIQ, Department of Defense, and The Henry M. Jackson Foundation for The Advancement of Military Medicine Partner to Deploy Continuous Remote Monitoring Platform to Study COVID-19

  5/7/2020

  This DOD-funded initiative will assess the role of home-based continuous biosensor data and AI analytics in addressing the global COVID-19 crisis.

• PhysIQ Applies Ebola Expertise to Fight COVID-19

  4/15/2020

  PhysIQ uses over one million hours of training set data to implement new machine learning analytics aimed at detecting early signs of COVID-19.

• PhysIQ’s Proprietary Personalized Analytics to be Used for COVID-19 Care with Newly Broadened FDA Labeling

  3/26/2020

  PhysIQ announces FDA-sanctioned labeling to address the COVID-19 public health emergency with its proprietary Multivariate Change Index (MCI) Deployed within the pinpointIQ ® continuous remote monitoring solution, physIQ’s MCI will be used to proactively monitor homebound patients with or vulnerable to COVID-19 The sophisticated, machine learning-based algorithm uses multiple continuous vital signs from wearable sensors to detect subtle chan

• PhysIQ and U.S. Veteran’s Affairs Publish Breakthrough Study Predicting Heart Failure Hospitalization up to 10 days in Advance using AI

  2/25/2020

  PhysIQ and the U.S. VA publish results of a clinical trial that demonstrates how artificial intelligence (AI) applied to continuous wearable sensor data may predict hospitalizations.

• PhysIQ Inc. Receives FDA Clearance of Continuous Ambulatory Respiration Rate Algorithm Enabling Artificial Intelligence-based Analytics for Biopharma Companies and Payers

  7/31/2019

  FDA 510(k) cleared Respiration Rate analytic adds to physIQ’s growing portfolio of FDA 510(k) algorithms

• Omron Healthcare and physIQ Partner to Transform Cardiovascular Patient Care

  2/6/2019

  - Omron HeartGuide®, the first wearable blood pressure device, will integrate with physIQ’s pinpointIQ® analytics platform to indicate a potential health risk - This combined solution is being deployed to help manage recently-discharged, at-risk patients - The goal is to provide clinicians with physiological insight to proactively address potential clinical deterioration

• With Latest FDA 510(k), physIQ Achieves Another Clearance as a Pioneer in AI Analytics

  9/11/2018

  FDA 510(k) cleared Atrial Fibrillation (AFib) detection analytic adds to physIQ’s portfolio of FDA 510(k) algorithms

• Netherlands-based Haga Teaching Hospital partners with physIQ and VitalConnect to continuously monitor cancer patients during treatment

  7/10/2018

  Cancer patients are equipped with wearable biosensors for monitoring before, during and after cancer treatment

• physIQ Snags $8 Million in Series B Financing

  7/25/2017